Teva Pharmaceutical Industries (NYSE:TEVA): Assessing Valuation After a 46% Share Price Rebound

Simply Wall St.01-05 05:31

Teva Pharmaceutical Industries (NYSE:TEVA) has quietly outperformed many large pharma names over the past year, with the stock climbing about 46% as investors warm to its turnaround and specialty-drug...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601637020?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","is_english":true,"pubTime":"2026-01-05 05:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601637020","market":"sg","top_or_hot":-1,"title":"Teva Pharmaceutical Industries (NYSE:TEVA): Assessing Valuation After a 46% Share Price Rebound","media":"Simply Wall St.","content":"<div>\n<p>Teva Pharmaceutical Industries (NYSE:TEVA) has quietly outperformed many large pharma names over the past year, with the stock climbing about 46% as investors warm to its turnaround and specialty-drug...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-nyseteva-assessing-valuation\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceutical Industries (NYSE:TEVA): Assessing Valuation After a 46% Share Price Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceutical Industries (NYSE:TEVA): Assessing Valuation After a 46% Share Price Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-05 05:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-nyseteva-assessing-valuation><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Teva Pharmaceutical Industries (NYSE:TEVA) has quietly outperformed many large pharma names over the past year, with the stock climbing about 46% as investors warm to its turnaround and specialty-drug...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-nyseteva-assessing-valuation\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-nyseteva-assessing-valuation","article_id":"2601637020","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-pharmaceutical-industries-nyseteva-assessing-valuation","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601637020","pubTimestamp":1767562264,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Teva Pharmaceutical Industries (NYSE:TEVA) has quietly outperformed many large pharma names over the past year, with the stock climbing about 46% as investors warm to its turnaround and specialty-drug pipeline.\nSee our latest analysis for Teva Pharmaceutical Industries.\nDespite a soft patch in the past week, Teva’s recent 1 month share price return of 8.75 percent and 3 year total shareholder return of 194.20 percent suggest momentum is still very much on its side.\nIf Teva’s rebound has you...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","NYSE":"纽交所","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4557":"大麻股","TEVA":"梯瓦制药","BK4007":"制药","BK4596":"哈里斯概念","BK4559":"巴菲特持仓","BK4584":"避孕概念","BK4566":"资本集团"},"translate_title":"梯瓦制药工业（纽约证券交易所股票代码：TEVA）：股价反弹46%后评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1.5,"NYSE":1.5},"content_text":"Teva Pharmaceutical Industries (NYSE:TEVA) has quietly outperformed many large pharma names over the past year, with the stock climbing about 46% as investors warm to its turnaround and specialty-drug pipeline. See our latest analysis for Teva Pharmaceutical Industries. Despite a soft patch in the past week, Teva’s recent 1 month share price return of 8.75 percent and 3 year total shareholder return of 194.20 percent suggest momentum is still very much on its side. If Teva’s rebound has you rethinking the pharma space, this could be a good moment to scan other potential opportunities among healthcare stocks. Yet after such a sharp rally and improving fundamentals, the key question now is whether Teva still trades at a meaningful discount to its intrinsic value, or if the market has already priced in the next leg of growth. Most Popular Narrative: 5.6% Undervalued With Teva closing at $30.95 versus a most popular narrative fair value of about $32.77, the story tilts toward modest upside driven by operating leverage.  The fair value estimate has risen moderately to approximately $32.77 from about $28.61, reflecting increased confidence in Teva’s medium term outlook. The future P/E multiple has increased meaningfully to roughly 21.4 times from about 18.7 times, which implies a higher valuation assigned to Teva’s forward earnings.  Read the complete narrative. Want to see why this narrative leans on accelerating earnings, fatter margins, and a richer future multiple than today’s market is implying? The full breakdown reveals the specific growth runway, profitability shift, and valuation bridge that underpin this fair value call, but you will need to dig into the narrative to see exactly how those moving parts line up. Result: Fair Value of $32.77 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, lingering dependence on a few branded drugs and Teva’s still hefty debt burden could quickly derail the upside if execution or pricing disappoints. Find out about the key risks to this Teva Pharmaceutical Industries narrative. Another View: Earnings Multiple Flags Richer Pricing While the narrative fair value points to modest upside, Teva’s current P/E near 49.8 times screens expensive beside the US pharmaceuticals average of 19.9 times and a 25.3 times fair ratio that the market could drift toward. This would mean less room for error if growth underdelivers. See what the numbers say about this price — find out in our valuation breakdown. NYSE:TEVA PE Ratio as at Jan 2026 Build Your Own Teva Pharmaceutical Industries Narrative If you want to stress test these assumptions or rely on your own homework, you can quickly build a personalized view in just minutes. Do it your way A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Looking for your next investment edge? Use the Simply Wall St Screener now to uncover fresh stock ideas that match your strategy so you are not left watching stronger opportunities pass by.  Capture mispriced quality by targeting these 875 undervalued stocks based on cash flows that combine solid fundamentals with attractive upside potential before the crowd catches on. Ride the next wave of innovation by focusing on these 25 AI penny stocks positioned at the heart of the artificial intelligence transformation. Explore potential income streams by scanning these 14 dividend stocks with yields > 3% offering yields that can contribute to your long term returns.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechValuation is complex, but we're here to simplify it.Discover if Teva Pharmaceutical Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601637020","isCrawlerRequest":true}